Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma

Heelan, 1999, Staging of malignant pleural mesothelioma, Am J Radiol, 172, 1039 Patz, 1992, Malignant pleural mesothelioma, Am J Roentgenol, 159, 961, 10.2214/ajr.159.5.1414807 Rusch, 1996, The importance of surgical staging in the treatment of malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 111, 815, 10.1016/S0022-5223(96)70342-2 Sugarbaker, 1999, Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 117, 54, 10.1016/S0022-5223(99)70469-1 Rusch, 2001, A phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 122, 788, 10.1067/mtc.2001.116560 Schneider, 2000, Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 120, 128, 10.1067/mtc.2000.106529 Bénard, 1998, Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography, Chest, 114, 713, 10.1378/chest.114.3.713 1995, A proposed new international TNM staging system for malignant pleural mesothelioma, Chest, 108, 1122, 10.1378/chest.108.4.1122 American Joint Committee on Cancer. AJCC cancer staging handbook. 6th ed. New York, Berlin: Springer 2002